Study supports expanding use of Aquadex kidney therapy to infants weighing 5 kg and above

Nuwellis announced publication of a multicenter study showing positive outcomes using its Aquadex SmartFlow System for kidney support in pediatric patients, including infants under 10 kg. The ULTRA-Peds Registry evaluated 91 children across seven hospitals, with 87% survival and 86.5% uninterrupted treatments. This evidence supports Nuwellis' plan to expand FDA labeling to include patients weighing 5 kg and above, addressing a critical need for kidney therapy in very small children. The study also highlights the system's technical reliability and potential to improve care for vulnerable pediatric patients.

Nuwellis Inc shares rose 4.90% to USD 3.21 on Pluang as of Oct 27, 2026 19:12 WIB. The stock shows a market cap of $1.24 million with a high sell order activity of 94%. Typical investors hold NUWE for about 29 days on the platform.